[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621077":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":29,"responsibleParty":48,"collaborators":50,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"HCC patients in atezo+bev treatment without TIPS",null,"Out of 350 HCC patients 168 patients with histologically confirmed, locally advanced or metastatic and\u002For unresectable liver cancer, without prior transjugular intrahepatic portosystemic shunting and receiving atezolizumab + bevacizumab treatment, will be assigned to analysis cohort 1: HCC patients in atezo+bev treatment without TIPS",{"label":13,"type":10,"description":14,"interventionNames":10},"HCC patients in atezo+bev treatment with TIPS","Out of 350 HCC patients 182 patients with histologically confirmed, locally advanced or metastatic and\u002For unresectable liver cancer, with prior transjugular intrahepatic portosystemic shunting and receiving atezolizumab + bevacizumab treatment, will be assigned to analysis cohort 1: HCC patients in atezo+bev treatment with TIPS",[16],{"name":17,"affiliation":18,"role":19},"Christoph Roderburg, Professor","Heinrich Heine University of Duesseldorf, University Hospital of Duesseldorf","PRINCIPAL_INVESTIGATOR",[21,25],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},"CONTACT","04969589978719","christoph.roderburg@med.uni-duesseldorf.de",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Bianca Zaepf","04969589978778","zaepf.bianca@ikf-khnw.de",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"University Hospital of Düsseldorf","RECRUITING","Düsseldorf","North Rhine-Westphalia","40225","Germany","DE",{"type":39,"coordinates":40},"Point",[41,42],6.77927,51.22319,{"lat":42,"lon":41},[45],{"name":46,"role":22,"phone":10,"phoneExt":10,"email":47},"Tom Lüdde, Professor","tom.luedde@med.uni-duesseldorf.de",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[51,54],{"name":52,"class":53},"Roche Pharma AG","INDUSTRY",{"name":55,"class":6},"Heinrich-Heine University, Duesseldorf","100621077","nis-on-the-benefits-of-tips-in-patients-with-hcc-receiving-atezobev-in-1st-line-therapy-100621077",false,"NCT07365930","NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy","Non-Interventional Study on the Benefits of Transjugular Intrahepatic Portosystemic Shunting in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab in First-Line Therapy","NISTIPS","Inclusion Criteria:\n\n1. The patient has a histologically confirmed, locally advanced or metastatic and\u002For unresectable HCC with:\n\n   1. the presence of liver cirrhosis (cirrhosis confirmed by histology or liver stiffness or with unequivocal signs in ultrasound, endoscopy, and\u002For blood tests),\n   2. a disease that is not amenable to curative surgical and\u002For locoregional therapies, or a progressive disease after surgical and \u002For locoregional therapies,\n2. A decision for treatment with atezolizumab + bevacizumab according to the market authorization with or without TIPS has been made before enrolling into the study by the treating physician.\n\nNOTE: Patients who have already received 1-2 cycles of atezo+bev therapy are eligible for enrollment into the NISTIPS TRITICC-4 study, when the prescription of the medicine or other therapeutic strategies are clearly separated from the decision to include the patient in the study.\n\nExclusion Criteria:\n\n1. The patient has not provided signed informed consent.\n2. The patient is under 18 years of age at the time of giving signed informed consent.\n3. The patient is unable to understand all implications of study participation.","ALL","18 Years",{"count":67,"type":68},350,"ESTIMATED","OBSERVATIONAL","The NISTIPS TRITICC-4 study is a prospective, multicentre, non-interventional cohort study to analyze the effectiveness of transjugular intrahepatic portosystemic shunting (TIPS) in patients with Hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab as first-line treatment. It will further characterize the effectiveness of atezolizumab and bevacizumab therapy, investigate post-market safety and evaluate health-related quality in HCC patient cohorts with or without TIPS in a real-world setting.",[72],"Hepatocellular Carcinoma (HCC)",[74,75,76,77,78,79,80,81,82,83],"HCC","TIPS","Tecentriq","Avastin","transjugular intrahepatic portosystemic shunting","Hepatocellular carcinoma","observational study","non-interventional study","Atezolizumab","Bevacizumab","2026-02-03",{"date":86,"type":87},"2026-02-05","ACTUAL",{"date":89,"type":87},"2025-12-17",{"date":91,"type":68},"2031-12-17",{"name":5,"class":6},1]